This page shows the latest lung cancer news and features for those working in and with pharma, biotech and healthcare.
new dosing option in locally advanced, unresectable non-small cell lung cancer (NSCLC). ... The new dosing regimen is consistent with Imfinzi’s approved dosing in extensive-stage small cell lung cancer (ES-SCLC).
The BTD covers the combination treatment in the first-line setting for people with metastatic non-small cell lung cancer (NSCLC), whose tumours have high PD-L1 expression and no EGFR ... outcomes for people with certain types of lung cancer,” said Levi
metastatic non-small cell lung cancer (NSCLC), who have received at least one prior systemic therapy. ... Amgen is due to submit the detailed results from the phase 2 study to the International Association for the Study of Lung Cancer World Conference on
Drug combination failed to improve overall survival rate. Jazz Pharmaceuticals and PharmaMar have revealed that their small cell lung cancer (SCLC) therapy lurbinectedin has failed to meet the primary endpoint in
Merck &Co (MSD) has agreed to acquire VelosBio for $2.75bn, giving MSD access to a number of potential cancer treatments in the process. ... breast cancer (TNBC), hormone receptor-positive and/or HER2-positive breast cancer and non-squamous non-small
In the third quarter, sales of Keytruda grew by 24% to $2.2bn reflecting growing momentum in a number of non-small cell lung cancer indications, as well as uptake in ... other areas including adjuvant melanoma and bladder cancer.
More from news
Approximately 108 fully matching, plus 834 partially matching documents found.
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical
The fatality rate was higher for patients with lung cancer and non-Hodgkin Lymphoma, at 15.7% and 9.4%, respectively. ... It also builds on previous studies demonstrating the cost-effectiveness of Zarxio as primary prophylaxis within patients with lung
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
the other is designed to engage with any tumour-specific antigen, for example DLL3 in small-cell lung cancer, PSMA in prostate cancer and CLDN18.2 and MUC17 in gastric or ... T cells only become activated and proliferate, with the goal of staying
As part of the Lung Ambition Alliance, a partnership with the International Association for the Study of Lung Cancer (IASLC), Guardant Health and the Global Lung Cancer Coalition (GLCC), AstraZeneca is ... working to validate relevant endpoints to
More from intelligence
Approximately 1 fully matching, plus 61 partially matching documents found.
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.
Pauporté will lead the clinical development of the firm's lung cancer candidate Tedopi, which is currently in phase III trials, and will be responsible for exploring the drug's potential ... She brings over 20 years of biomedical and clinical research
Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice
lung cancer therapy, which is expected in 2017. ... bring new therapeutic options to patients living with cancer.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
The Hispanic population is underrepresented in lung cancer trials despite experiencing different health outcomes to white people. ... The Hispanic population is generally not represented in lung cancer trials because of limited access and few research
Black people are among those who typically suffer poorer health outcomes from lung cancer. ... Early next year, a Stand Up To Cancer Innovation Summit will launch the project, which will bring together lung cancer experts with researchers specializing in
Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. ... 2017 Jul 11; 318(2):197-198. Denis F, Basch E et al. Two-Year Survival Comparing Web-Based Symptom Monitoring vs Routine
lung cancer, have shown the value of bringing these kinds of services closer to patients’ homes. ... For example, most lung cancer diagnoses are made at stage four.
More from PMHub
Approximately 2 fully matching, plus 15 partially matching documents found.
11 London is a strategic and creative agency working in the fields of health and humanity – complex areas, but...